Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test

28th Jan 2021 14:42

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Enters into collaboration with Massachusetts-based Bruker Corp to assess SARS-CoV-2 assay Avacta developed alongside Adeptrix Inc, also based in Massachusetts. "Bruker is one of the world's leading analytical instrumentation companies providing high-performance scientific instruments and high-value analytical and diagnostic solutions to scientists globally," Avacta says.

Current stock price: 125.90 pence, down 7.4% on Thursday

Year-to-date change: up 10%

By Eric Cunha; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.


Related Shares:

Avacta Group
FTSE 100 Latest
Value8,809.74
Change53.53